This article has Open Peer Review reports available.
Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells
© Taylor et al; licensee BioMed Central Ltd. 2011
Received: 3 May 2011
Accepted: 1 November 2011
Published: 1 November 2011
Tumor Necrosis Factor-α Related Apoptosis Inducing Ligand (TRAIL) and agonistic antibodies to death receptor 4 and 5 are promising candidates for cancer therapy due to their ability to induce apoptosis selectively in a variety of human cancer cells, while demonstrating little cytotoxicity in normal cells. Although TRAIL and agonistic antibodies to DR4 and DR5 are considered safe and promising candidates in cancer therapy, many malignant cells are resistant to DR-mediated, TRAIL-induced apoptosis. In the current work, we screened a small library of fifty-five FDA and foreign-approved anti-neoplastic drugs in order to identify candidates that sensitized resistant prostate and pancreatic cancer cells to TRAIL-induced apoptosis.
FDA-approved drugs were screened for their ability to sensitize TRAIL resistant prostate cancer cells to TRAIL using an MTT assay for cell viability. Analysis of variance was used to identify drugs that exhibited synergy with TRAIL. Drugs demonstrating the highest synergy were selected as leads and tested in different prostate and pancreatic cancer cell lines, and one immortalized human pancreatic epithelial cell line. Sequential and simultaneous dosing modalities were investigated and the annexin V/propidium iodide assay, in concert with fluorescence microscopy, was employed to visualize cells undergoing apoptosis.
Fourteen drugs were identified as having synergy with TRAIL, including those whose TRAIL sensitization activities were previously unknown in either prostate or pancreatic cancer cells or both. Five leads were tested in additional cancer cell lines of which, doxorubicin, mitoxantrone, and mithramycin demonstrated synergy in all lines. In particular, mitoxantrone and mithramycin demonstrated significant synergy with TRAIL and led to reduction of cancer cell viability at concentrations lower than 1 μM. At these low concentrations, mitoxantrone demonstrated selectivity toward malignant cells over normal pancreatic epithelial cells.
The identification of a number of FDA-approved drugs as TRAIL sensitizers can expand chemotherapeutic options for combination treatments in prostate and pancreatic cancer diseases.
Tumor Necrosis Factor-α Related Apoptosis Inducing Ligand (TRAIL) is a member of the Tumor Necrosis Factor (TNF) super-family of cytokines that engages the cellular apoptotic mechanism upon specific binding to death receptors (DRs) 4 and 5 on the cell surface . TRAIL has attracted significant attention in recent years due to its ability to selectively induce apoptosis in transformed (malignant) cells while demonstrating little cytotoxicity in normal cells [2–7]. TRAIL binds cell-surface death receptors (DR4 and DR5) as a homotrimer and triggers the formation of the Death-Inducing Signaling Complex (DISC); the Fas-Associated Death Domain (FADD) and caspases 8 or 10 are recruited to the DISC from the cytoplasm. The proteolytic activation of initiator caspases leads to the subsequent activation of executioner caspases (e.g. caspase-3), which ultimately results in apoptosis in Type I Cells. Activation of caspase-8 engages the mitochondria-amplified apoptosis machinery in Type II cells . The binding of TRAIL to decoy receptors (DcR) 1 and 2 has also been demonstrated; it is hypothesized that these receptors play a role in maintaining the homeostasis of TRAIL activity in vivo [2, 8].
Recombinant TRAIL induces apoptosis in a variety of human cancer cell lines including those of breast, colon, lung, prostate, liver, leukemia, lymphoma, and neuroblastoma [4, 6, 8, 9]. TRAIL has also demonstrated potent anti-tumor activity in a number of xenograft models including those of colon and breast carcinomas [10–12]. Soluble TRAIL variants are well tolerated in mice and chimpanzees  and demonstrate minimal cytotoxicity towards primary human hepatocytes and endothelial cells in culture [7, 14]. As a consequence of the selectivity towards malignant cells, certain TRAIL formulations (e.g. non-histidine tagged TRAIL) are considered safe for potential therapeutic applications .
Although TRAIL and agonistic antibodies to death receptors 4 and 5 are promising candidates for cancer therapy, many tumor cells are inherently resistant or acquire resistance to TRAIL-mediated apoptosis. Commonly implicated resistance mechanisms include dysfunction of the Fas-Associated Death Domain (FADD)/improper assembly of the Death-Inducing Signaling Complex (DISC) , loss of caspase-8 activity [17–19], constitutively active Akt/protein kinase B , and over-expression of anti-apoptotic proteins such as c-Flip [16, 21] and Bcl-2 . As a result, therapeutic strategies involving DNA-damaging radiotherapy [23, 24], genotoxins [25, 26], and peptides  have been investigated for enhancing cancer cell sensitivity to TRAIL  and/or agonistic antibodies against DR4/DR5 .
Here, we report the parallel screening of fifty-five FDA-approved and foreign-approved chemotherapeutic drugs in order to identify existing anti-cancer drugs that might act as TRAIL sensitizers in resistant prostate and pancreatic cancer cells. Drugs were first pre-screened individually (single agent treatment) for toxicity at a concentration of 20 μM using TRAIL-resistant PC3-TR prostate cancer cells; candidates that resulted in greater than 70% reduction in cancer cell viability were screened for TRAIL sensitization activity at a lower concentration of 10 μM. A total of fourteen potential TRAIL sensitizer leads, including six whose TRAIL sensitization activities were previously unknown, were identified from the screen. Five leads were further characterized in prostate and pancreatic cancer cells.
Two human prostate cancer cell lines (PC3, and PC3-TR), three human pancreatic cancer lines (Panc-1, MIAPaCa2, and BXPC-3) and one immortalized human pancreatic epithelial cell line (HPDE6) were used in the current study. PC3-TR (TR: TRAIL resistant)  cells were a generous gift from Dr. Aria Olumi at the Massachusetts General Hospital in Boston, MA. Cells were grown in 75 cm2 Corning cell culture flasks with RPMI 1640 tissue culture media supplemented with 10% Fetal Bovine Serum and 1% penicillin/streptomycin (10000 units/mL penicillin G and 10000 μg/mL streptomycin) at 37°C with 5% CO2.
The Johns Hopkins Chemical Compound Library (JHCCL)  was purchased from The Johns Hopkins University School of Medicine. The library contains a total of 1514 FDA- and foreign-approved drugs. The anti-neoplastic plate (plate #1) consists of 55 FDA-approved approved anti-cancer drugs and was employed in the screen for identifying TRAIL sensitizers. All stock solutions of the drugs from the library were supplied at a concentration of 10 mM in either DMSO or water. For expanded dose-response experiments, additional doxorubicin and mitoxantrone were purchased from Sigma while gemcitabine, mithramycin, and thioTEPA were obtained through the NCI/NIH Developmental Therapeutic Program. TRAIL was purchased from R&D Systems and reconstituted in PBS at a 10 μg/mL stock concentration in 50 μL aliquots to prevent multiple freeze/thaw cycles. All solutions were prepared to ensure that the final solvent (DMSO or water) concentration in cell treatments would be less than 1% (v/v) to limit non-specific activity.
Single Agent and Combination Treatments
Cells were plated in 96 well plates at a density of 8,400 cells/well and incubated at 37°C and 5% CO2 for approximately 24 hours. For single-agent treatments, cells were exposed to drug candidates at a concentration of 20 μM for 24 hours at which point, cell viability was determined using the MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay (described below). Single-agent TRAIL treatments were carried out similarly; a dose range of 0-100 ng/mL of TRAIL was used. For sequential combination treatments, cells were first treated with a sensitizer drug candidate for 24 hours. The media was then removed, replaced with fresh serum-containing media, and the cells were treated with TRAIL. Cells were incubated for an additional 24 h after which, viability measurements were carried out using the MTT assay. In order to determine if dosing of the combination treatment had an effect on the efficacy, simultaneous combination treatments were carried out by treating cells with the sensitizer drug and TRAIL at the same time for 24 h at which point, cancer cell viability was determined using the MTT assay.
Determination of Cell Viability
Cell viability was assessed using the MTT cell proliferation assay (ATCC CA#30-1010k). Following addition of the MTT reagent (2 h at 37°C), cells were treated with a lysis buffer from the kit and kept at room temperature in the dark for two hours in order to carry out complete lysis and to solubilize the MTT product. The absorbance of each well was measured using a Biotech Synergy 2 Multi-Detection Microplate Reader at 570 nm. Each experiment included a set of blank wells (media only), a live control (no treatment) and a dead control (200 μL of 10 μM H2O2 or 1.5 μL of 20 μM Quillaja were employed for inducing death in the cell population). Background absorbance was measured using the blank and subtracted from all absorbance measurements. In the case of drugs that potentially interfered with the assay, a separate set of media-only wells were treated with equivalent volumes of the drug, and the measured absorbance was subtracted as the background. This was carried out to eliminate any bias caused by the natural absorbance of the drug itself. Fractional cell viability was calculated as: (OD of sample - OD of dead control)/(OD of live control - OD of dead control) where OD is the optical density. Percentage cell viability was calculated by multiplying the fractional viability by 100. Data are plotted as percentage reduction in cell viability compared to control (untreated cells) in which, a 0% value on the graph means 100% viability and 100% value on the graph means 0% viability.
Screening experiments were carried out in duplicate and expanded dose responses with identified leads were performed at least in triplicate. Data are presented as the mean ± one standard deviation. The standard deviation of each set was calculated based on the variation between experiments. ANOVA was performed using the t-test function in Microsoft Excel. Analysis of the single-agent treatment was performed in order to determine whether or not a drug had a significant effect when compared to the live (untreated) control. Efficacies of sensitization were determined by comparing the decrease in cell viability following combination treatments (i.e. drug in combination with TRAIL) to the reduction in cell viability as a consequence of the additive effect of single-agent treatments (drug alone + 10 ng/mL TRAIL alone).
As an alternate assessment of cell viability, a calcein AM/ethidium homodimer-1 (EthD-1) viability/cytotoxicity kit (Invitrogen L3224) was used to measure treatment efficacy for a select set of combination treatments. Briefly, a working solution of 2 μM calcien AM and 4 μM ethidium homodimer-1 (EthD-1) was prepared in a solution of sterile 1× PBS. The working solution was then added to each well of the cell culture plate and incubated at 37°C with 5% CO2 for 30-45 minutes. Fluorescence imaging was then carried out using a Zeiss Observer D1 fluorescent microscope. A 38 HE filter set (Excitation: 470/40; Emission: 525/50) was used to image the fluorescence of the calcein AM (green fluorescence) while a 43 HE filter set (Excitation: 550/25; Emission: 605/70) was used to measure the fluorescence of the EthD-1 (red fluorescence).
Annexin V and Propidium Iodide Analysis
An annexin V/propidium iodide assay (Invitrogen L3224) was carried out to determine if combination treatments induced apoptosis in cells. Briefly, a working solution of 2% annexin V and 1 μg/mL propidium iodide (PI) was prepared in a solution of 1× annexin binding buffer. The working solution was added to each well of the cell culture plate and incubated at room temperature for 15-20 minutes. Fluorescence imaging was then performed using a Zeiss Observer D1 fluorescent microscope. A 38 HE filter set (Excitation: 470/40; Emission: 525/50) was used to measure the fluorescence of the annexin V (green fluorescence) while a 43 HE filter set (Excitation: 550/25; Emission: 605/70) was used to measure the fluorescence of the propidium iodide (red fluorescence).
All image processing was performed using ImageJ  image processing software. For the live/dead analysis the threshold of the fluorescent image was adjusted so that any background noise was removed and that the boundary between individual cells was well defined. The image was then converted to a binary format. In some cases, it was difficult to differentiate between cell boundaries in which case the Watershed process was used to distinguish between individual cells while ensuring that any cells that were incorrectly divided were accounted for . The "Analyze Particles" function was then used to obtain a final cell count. The live cell count was then normalized against the live control cell count to give an indication of the cell viability. The brightness of the images was adjusted so that the background had zero pixel intensity value in case of annexin V/PI analyses. Next, false color was applied to the image; green was applied for the annexin V stains and red was applied to the PI stains.
Results and discussion
In the current study, we screened a small library of fifty-five FDA- and foreign-approved antineoplastic drugs from the Johns Hopkins Clinical Compound Library (JHCCL) in order to identify chemotherapeutics that sensitize prostate and pancreatic cancer cells to TRAIL-induced apoptosis. Identification of FDA-approved drugs as TRAIL sensitizers is an attractive discovery strategy since it is possible to rapidly translate these novel combinations to the clinic. PC3-TR (TR: TRAIL resistant) human prostate cancer cells were used in the primary screening, since it was hypothesized that lead candidates discovered for this resistant cell line might be relevant to clinical phenotypes that develop resistance to TRAIL. The cell line demonstrated low susceptibility to single-agent TRAIL treatments; a 20% loss of viability reduction was observed in PC3-TR cells at concentrations as high as 100 ng/mL (Additional File 1). We employed a TRAIL concentration of 10 ng/mL in subsequent combination treatment experiments in order to keep the TRAIL dose at a minimum; under these conditions, single-agent TRAIL induced a loss of viability in approximately 4% of the PC3-TR cell population. To our knowledge, these are the first screening experiments carried out with the PC3-TR TRAIL-resistant prostate cancer cell line.
Identification of FDA-Approved Drugs as TRAIL Sensitizers in Prostate and Pancreatic Cancer Cell Lines using Parallel Screening
Summary of drugs identified as TRAIL sensitizing agents and their previously known activity.
Drug Alone + TRAIL Alone
Known TRAIL Sensitizer?
Known TRAIL Sensitizer in Prostate Cancer?
Known TRAIL Sensitizer in Pancreatic Cancer?
From the TRAIL chemosensitizer leads identified above, five drugs - doxorubicin, gemcitabine, mithramycin, mitoxantrone, and thioTEPA were chosen for additional evaluation. These drugs have been approved by the FDA for chemotherapeutic administration in different malignancies. Doxorubicin and gemcitabine were selected since both have been previously characterized as TRAIL-sensitizing agents in prostate and/or pancreatic cancer cells [21, 38–41]. Mithramycin has also been shown to sensitize prostate cancer cells to TRAIL  but to our knowledge, the drug has not been previously demonstrated to possess TRAIL sensitization activity in pancreatic cancer cells. Neither mitoxantrone nor thioTEPA has previously been shown to act as TRAIL sensitizers in cancer cells to the best of our knowledge. Additional factors that were used to determine candidates for subsequent characterization included single-agent drug toxicities in the PC3-TR cell line (drugs with lower toxicities were given preference), the total loss of cancer cell viability induced by the combination treatment compared to the single agent treatments, and prior knowledge of the drugs as TRAIL sensitizers.
Additional evaluation involved expanding the range of the drug dose from 0 to 20 μM for doxorubicin and 0 to 100 μM for the other drugs in PC3-TR and PC3 human prostate cancer cells, and the Panc-1 human pancreatic cell cancer line. It is important to note that the screening experiments employed drugs from the JHCCL (frozen 10 mM aliquots), while the lead characterization experiments employed drugs obtained from Sigma (doxorubicin, mitoxantrone) and the NCI/NIH Developmental Therapeutic Program (gemcitabine, mithramycin, thioTEPA) which were reconstituted in either DMSO or water, based on the solvent that was used for the respective drugs supplied in the JHCCL.
Combination treatments were carried out with 10 ng/mL TRAIL, which induced a loss of viability of 4.3% (+/- 3.2%) in PC3-TR cells, 8.4% (+/- 4.2%) in PC3 cells, and 1.4% (+/- 7.4%) in Panc-1 cells, when administered alone. Such low levels of viability loss are demonstrative of the resistance of these cancer cells to TRAIL-induced apoptosis. It is important to note that while PC3-TR cells are derived from PC3 cells, the two lines are inherently different and therefore, it can be expected that the two cell lines respond differently to drug treatments. For example, we have previously shown that closely related prostate cancer cell lines, PC3 and PC3-PSMA cells, demonstrate markedly different behavior in response to nanoparticle treatment .
The median concentrations of single-agent doxorubicin (Figure 3) that resulted in 50% loss of viability in the cancer cell population compared to the untreated control (LC50) were approximately 0.6 μM, 6 μM and 0.6 μM in PC3-TR, PC3, and Panc-1 cells, respectively. However, in combination with 10 ng/mL TRAIL, the LC50 values for doxorubicin were 0.25 μM for PC3-TR and PC3 cells, and 0.1 μM (100 nM) for Panc-1 cells, all of which are substantially lower than the single-agent concentrations (Figure 3). The greatest loss of cancer cell viability for the doxorubicin-TRAIL combination treatment compared to single-agent doxorubicin treatment was observed at 0.33 μM (42%), 1 μM (44.4%), and 0.33 μM (55%) for PC3-TR, PC3, and Panc-1 cells, respectively (Figure 3). The cytotoxic effect of doxorubicin is attributed to its DNA intercalation as well as its disruption of cellular functions upon cell membrane binding. Intercalation inhibits nucleotide replication via the stabilization of type II topoisomerase . Doxorubicin is currently approved for the treatment of acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, breast cancer, ovarian cancer, transitional cell bladder cancer, thyroid cancer, gastric cancer, Hodgkin's disease, malignant lymphoma, bronchogenic cancer, ovarian cancer, AIDS-Related Kaposi's sarcoma, and multiple myeloma. The TRAIL sensitization activities of doxorubicin are due to the ability of the drug to down-regulate the anti-apoptotic protein c-FLIP [38, 44], activate pro-apoptotic caspases [45, 46] and induce reactive oxygen species (ROS) formation in cancer cells . Thus, the genotoxic activity of doxorubicin activates the internal apoptosis pathway, while simultaneously sensitizing the cell to external, receptor-mediated apoptosis by the TRAIL ligand.
The LC50 values for single-agent mithramycin were 20 μM, 0.5 μM and 6 μM for PC3-TR, PC3, and Panc-1 respectively. However, in combination with 10 ng/mL TRAIL, the LC50 values for mithramycin were approximately 0.2 μM for PC3-TR and PC3 cells, and 0.1 μM for Panc-1 cells, respectively (Figure 4). Combination treatments with mithramycin (plicamycin) demonstrated the greatest enhancement in loss of cancer cell viability at 6.6 μM (50.5%), 0.66 μM (24.9%) and 0.33 μM (48.6%) in PC3-TR, PC3, and Panc-1 cells respectively, compared to single-agent mithramycin treatment (Figure 4). Importantly, mithramycin demonstrated one of the highest efficacies in combination with TRAIL; a difference of 67% in loss of cancer cell viability was seen for the combination treatment compared to the additive effect of the single-agent treatments (67% increase; Figure 1). Mithramycin is an antineoplastic antibiotic derived from Streptomyces and is approved by the FDA for the treatment of testicular cancer and hypercalcaemia . The antineoplastic properties of mithramycin are likely linked to the binding of mithramycin to GC-rich section of DNA and the subsequent inhibition of RNA synthesis and regulation of transcription . The TRAIL-sensitization activity of mithramycin is not very well characterized, but one study suggests that this activity is caused by the down regulation of X-linked Inhibitor of Apoptosis Protein (XIAP) . XIAP inhibits apoptosis by binding to and inhibiting caspases 3, 7 and 9. Mithramycin is able to prevent the transcription of XIAP through its binding activity to DNA [37, 48]. This action would sensitize cancer cells to both, intrinsic and extrinsic apoptosis pathways. However, the extent to which mithramycin activated the intrinsic pathway has not been elucidated.
LC50 values for single-agent mitoxantrone were approximately 10 μM for PC3-TR and PC3 cells, and 5 μM for Panc-1 cells. However, in combination with 10 ng/mL TRAIL, the LC50 values for mitoxantrone were significantly reduced to 0.6 μM, 0.1 μM and 1 μM for PC3-TR, PC3 and Panc-1 cells, respectively (Figure 5). In the case of mitoxantrone-TRAIL combination treatment, the greatest enhancement in loss of viability was observed at 6.6 μM (55.0%) in PC3-TR, 0.33 μM (60.8%) in PC3, and 6.6 μM (38.5%) in Panc-1 cells (Figure 5), compared to mitoxantrone alone. The chemotherapeutic activity of mitoxantrone is attributed to its ability to intercalate into DNA, resulting in cross-links and strand breaks. Additionally, mitoxantrone also interferes with RNA synthesis and inhibits topoisomerase II . Mitoxantrone has been approved by the FDA for palliative treatment of prostate cancer and curative treatment of acute nonlymphocytic leukemia; the drug has also been recently approved for the treatment of multiple sclerosis. Although we did not find reports that describe the use of mitoxantrone as a TRAIL sensitizer, mitoxantrone has been demonstrated to possess synergistic relationship with Tumor Necrosis Factor (TNF) for inducing apoptosis in cells [51, 52]. A detailed evaluation that describes the mechanisms behind the TRAIL-sensitization activity of mitoxantrone is currently under investigation in our laboratory.
In the case of gemcitabine, statistically significant enhancement of viability reduction occurred in PC3-TR at concentrations above 6.6 μM (Additional File 4). Further increase in concentration to 100 μM resulted in an enhancement of cell viability loss up to a maximal value of 29% for the combination treatment over the single drug treatment. Gemcitabine is currently approved for the treatment of ovarian cancer (with carboplatin), breast cancer (with paclitaxel), non-small cell lung cancer (with cisplatin), and pancreatic cancer. Gemcitabine is metabolized intercellularly to active diphosphate and triphosphate nucleosides which work via two mechanisms to inhibit DNA synthesis. First, gemcitabine diphosphate inhibits the enzyme ribonucleotide reductase, which is a catalyst of reactions to form deoxynecleoside triphosphates. Second, gemcitabine triphosphate competes with other deoxynecleoside triphosphates for incorporation into DNA, which is enhanced by the action of gemcitabine diphosphate. Although the TRAIL sensitization activity of gemcitabine is not fully understood, it is hypothesized that the response is related to the activation of pro-apoptotic caspases [26, 41]. Previous results have shown that the combination treatment of gemcitabine and TRAIL increases the activation of caspases 8 and 3, while a single agent treatment of gemcitabine increases the activation of only caspase 3 . Although synergy was observed in PC3-TR cells with gemcitabine, we did not see synergy between gemcitabine and TRAIL in PC3 and Panc-1 cells, which differs from other reports in the literature [26, 41]. This is likely due to differences in the concentrations of both drug and TRAIL conditions that were employed in these other studies; for example, other studies have employed 100 ng/mL TRAIL, which is ten-fold higher than the concentration used in our study [26, 41].
ThioTEPA has been approved by the FDA for the treatment of breast cancer, ovarian cancer, superficial papillary carcinoma of urinary bladder, lymphosarcoma, and Hodgkin's disease. ThioTEPA is a radiomimetic drug that can produce ethylenimine radicals, which disrupt DNA. ThioTEPA showed a 40% difference in viability reduction between the combination treatments and the additive effect of the single agent treatments in the initial screen with PC3-TR; however, only an 8% increase was observed in case of the combination treatment compared to individual treatments in the subsequent experiments (Figure 2 & Additional File 5). This might be due to the different sources of the drug employed in the screening and characterization experiments.
The Combination Treatment of Low-dose Mitoxantrone and TRAIL is Selective towards Malignant Pancreatic Cells Compared to Normal Pancreatic Epithelial Cells
With the exception of gemcitabine and thioTEPA, the largest enhancements in viability reduction occurred at sub-micromolar or low micromolar concentrations for the other drugs. This is significant since the use of lower concentrations of these genotoxins can reduce damage to healthy tissue during therapy. This was demonstrated further by comparing single-agent verses the combination treatment LC50 values for each of the chemotherapeutic drugs. In the case of doxorubicin, mithramycin and mitoxantrone, the LC50 values decreased when each of these drugs was used in combination with TRAIL regardless of the cell line. With doxorubicin, this decrease in the LC50 value was relatively small in PC3-TR (0.6 μM to 0.25 μM) and Panc-1 (0.6 μM to 0.1 μM) cells, but significant in PC3 cells (6 μM to 0.25 μM). Mithramycin exhibited a relatively small change in the LC50 value for PC3 cells (0.5 μM to 0.2 μM), a moderate change for Panc-1 cells (6 μM to 0.1 μM), and the largest total change for PC3-TR cells (20 μM to 0.2 μM). Mitoxantrone demonstrated a moderate decrease in the LC50 value for Panc-1 cells (5 μM to 1 μM) and significantly larger decreases in LC50 values for the drug in combination with TRAIL in both, PC3-TR (10 μM to 0.6 μM) and PC3 (10 μM to 0.1 μM) cells.
Higher Concentrations of TRAIL in Combination Treatments do not Demonstrate Increased Efficacies
Sequential vs. Simultaneous Combination Treatments
The overall increase in loss of cancer cell viability between the lowest concentration of mitoxantrone (0.33 μM) and the highest concentration of mitoxantrone (100 μM) for the simultaneous treatments is about 25% (Figure 10), compared to 65% for sequential treatments. Interestingly, mithramycin did not show large differences in the loss of cell viability between the sequential and the simultaneous combination treatments. The difference between the two drugs and their dependence on treatment order is likely most closely related to the kinetics of how each drug is processed and how quickly the sensitization effect is achieved. In the case of mithramycin it is likely that the kinetics of sensitization are rapid and that even when the drugs are co-administered, there is sufficient time for the drug to sensitize the cells to TRAIL mediated apoptosis. On the other hand, it is possible that the kinetics of sensitization are slower for mitoxantrone and that the synergy between mitoxantrone and TRAIL is highest when the drug has sufficient time to overcome cellular resistances to TRAIL. We are currently following up on these observations in our laboratory.
Mitoxantrone-TRAIL and Mithramycin-TRAIL Combinations induce Apoptosis in PC3-TR Cells
In the current study, fifty-five FDA- and foreign-approved antineoplastic drugs were screened in order to identify chemotherapeutic candidates that sensitized malignant prostate and pancreatic cells to TRAIL-induced apoptosis. The initial screen was performed using a TRAIL resistant prostate cancer cell line (PC3-TR) and several drugs were identified as potential sensitizing agents. The screen was able to identify drugs with previously unknown TRAIL sensitization activities in prostate as well as pancreatic cancer cells, which can lead to the identification of new chemotherapeutic drug combinations and therefore potentially increase therapeutic options against these malignancies. Future work will involve expansion of the screen to other drug candidates, a detailed investigation into the mechanisms responsible for the sensitization activities of the leads and an evaluation of their efficacy in relevant animal models of prostate and pancreatic tumors.
The authors thank Professor Christina Voelkel-Johnson at the Medical University of South Carolina for several helpful discussions. The authors thank Professor Aria Olumi at Massachusetts General Hospital in Boston, MA for PC3-TR cells and Dr. Ming-Sound Tsao at the Ontario Cancer Institute in Canada for the HDPE6 cells. The authors thank Ms. Sally Hausman and the Cancer Therapeutics Evaluation Program (CTEP) at the National Cancer Institute for providing gemcitabine, mithramycin, and thioTEPA. Mr. David Taylor is a recipient of the Achievement Rewards for College Scientists (ARCS) Foundation fellowship and was partially supported by a Dean's fellowship at ASU. Ms. Christine Parsons was a Fulton Undergraduate Research Initiative (FURI) awardee at ASU. This study was funded by the National Cancer Institute, National Institutes of Health Grant 5R21CA131891-02 to KR and AJ.
- Zhang L, Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005, 12 (3): 228-237. 10.1038/sj.cgt.7700792.View ArticlePubMedGoogle Scholar
- Almasan A, Ashkenazi A: Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 2003, 14 (3-4): 337-348. 10.1016/S1359-6101(03)00029-7.View ArticlePubMedGoogle Scholar
- Baetu TM, Hiscott J: On the TRAIL to apoptosis. Cytokine Growth Factor Rev. 2002, 13 (3): 199-207. 10.1016/S1359-6101(02)00006-0.View ArticlePubMedGoogle Scholar
- Bouralexis S, Findlay DM, Evdokiou A: Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis. 2005, 10 (1): 35-51. 10.1007/s10495-005-6060-0.View ArticlePubMedGoogle Scholar
- Fiorucci G, Vannucchi S, Chiantore MV, Percario ZA, Affabris E, Romeo G: TNF-related apoptosis-inducing ligand (TRAIL) as a pro-apoptotic signal transducer with cancer therapeutic potential. Curr Pharm Des. 2005, 11 (7): 933-944. 10.2174/1381612053381729.View ArticlePubMedGoogle Scholar
- Kelley SK, Ashkenazi A: Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol. 2004, 4 (4): 333-339. 10.1016/j.coph.2004.02.006.View ArticlePubMedGoogle Scholar
- Thorburn A: Death receptor-induced cell killing. Cell Signal. 2004, 16 (2): 139-144. 10.1016/j.cellsig.2003.08.007.View ArticlePubMedGoogle Scholar
- Sheikh MS, Fornace AJ: Death and decoy receptors and p53-mediated apoptosis. Leukemia. 2000, 14 (8): 1509-1513. 10.1038/sj.leu.2401865.View ArticlePubMedGoogle Scholar
- Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004, 95 (10): 777-783. 10.1111/j.1349-7006.2004.tb02181.x.View ArticlePubMedGoogle Scholar
- Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA: Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 2002, 62 (20): 5800-5806.PubMedGoogle Scholar
- Singh TR, Shankar S, Chen X, Asim M, Srivastava RK: Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 2003, 63 (17): 5390-5400.PubMedGoogle Scholar
- Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A: Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Res. 2006, 66 (10): 5363-5370. 10.1158/0008-5472.CAN-05-4386.View ArticlePubMedGoogle Scholar
- Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA: Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther. 2001, 299 (1): 31-38.PubMedGoogle Scholar
- Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, et al: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med. 2001, 7 (4): 383-385. 10.1038/86397.View ArticlePubMedGoogle Scholar
- Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL, Schader MB, Untergasser A, Stremmel W, Walczak H: Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res. 2006, 12 (8): 2640-2646. 10.1158/1078-0432.CCR-05-2635.View ArticlePubMedGoogle Scholar
- Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P: Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 1999, 59 (11): 2747-2753.PubMedGoogle Scholar
- Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, Ikegaki N, Brodeur GM, Phillips PC: Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene. 2000, 19 (40): 4604-4610. 10.1038/sj.onc.1203816.View ArticlePubMedGoogle Scholar
- Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N: Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med Pediatr Oncol. 2000, 35 (6): 608-611. 10.1002/1096-911X(20001201)35:6<608::AID-MPO25>3.0.CO;2-U.View ArticlePubMedGoogle Scholar
- Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N: Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2000, 60 (16): 4315-4319.PubMedGoogle Scholar
- Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK: Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate. cancer Oncogene. 2001, 20 (42): 6073-6083.View ArticlePubMedGoogle Scholar
- White SJ, Lu P, Keller GM, Voelkel-Johnson C: Targeting the Short Form of cFLIP by RNA Interference is Sufficient to Enhance TRAIL Sensitivity in PC3 Prostate Carcinoma Cells. Cancer Biol Ther. 2006, 5 (12): 1618-1623. 10.4161/cbt.5.12.3352.View ArticlePubMedGoogle Scholar
- Fulda S, Meyer E, Debatin KM: Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene. 2002, 21 (15): 2283-2294. 10.1038/sj.onc.1205258.View ArticlePubMedGoogle Scholar
- Kim MR, Lee JY, Park MT, Chun YJ, Jang YJ, Kang CM, Kim HS, Cho CK, Lee YS, Jeong HY, et al: Ionizing radiation can overcome resistance to TRAIL in TRAIL-resistant cancer cells. FEBS Lett. 2001, 505 (1): 179-184. 10.1016/S0014-5793(01)02816-2.View ArticlePubMedGoogle Scholar
- Shankar S, Singh TR, Srivastava RK: Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate. 2004, 61 (1): 35-49. 10.1002/pros.20069.View ArticlePubMedGoogle Scholar
- Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T: Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene. 2003, 22 (13): 2034-2044. 10.1038/sj.onc.1206290.View ArticlePubMedGoogle Scholar
- Zisman A, Ng CP, Pantuck AJ, Bonavida B, Belldegrun AS: Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J Immunother. 2001, 24 (6): 459-471. 10.1097/00002371-200111000-00003.View ArticlePubMedGoogle Scholar
- Barua S, Linton RS, Gamboa J, Banerjee I, Yarmush ML, Rege K: Lytic peptide-mediated sensitization of TRAIL-resistant prostate cancer cells to death receptor agonists. Cancer Lett. 2010, 293 (2): 240-253. 10.1016/j.canlet.2010.01.012.View ArticlePubMedGoogle Scholar
- Sun SY, Yue P, Lotan R: Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. Oncogene. 2000, 19 (39): 4513-4522. 10.1038/sj.onc.1203810.View ArticlePubMedGoogle Scholar
- Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF: Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res. 2004, 64 (19): 7086-7091. 10.1158/0008-5472.CAN-04-1498.View ArticlePubMedGoogle Scholar
- Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ: A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol. 2006, 2 (8): 415-416. 10.1038/nchembio806.View ArticlePubMedGoogle Scholar
- Abramoff MD, Magalhães PJ, Ram SJ: Image processing with ImageJ. Biophotonics International. 2004, 11 (7): 36-42.Google Scholar
- Papadopulos F, Spinelli M, Valente S, Foroni L, Orrico C, Alviano F, Pasquinelli G: Common tasks in microscopic and ultrastructural image analysis using ImageJ. Ultrastructural Pathology. 2007, 31 (4-6): 401-407.View ArticlePubMedGoogle Scholar
- Jones DT, Ganeshaguru K, Mitchell WA, Foroni L, Baker RJ, Prentice HG, Mehta AB, Wickremasinghe RG: Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand. British journal of haematology. 2003, 121 (5): 713-720. 10.1046/j.1365-2141.2003.04340.x.View ArticlePubMedGoogle Scholar
- Wu XX, Kakehi Y, Mizutani Y, Kamoto T, Kinoshita H, Isogawa Y, Terachi T, Ogawa O: Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. International journal of oncology. 2002, 20 (5): 949-954.PubMedGoogle Scholar
- Gliniak B, Le T: Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer research. 1999, 59 (24): 6153-6158.PubMedGoogle Scholar
- Meinhold-Heerlein I, Borges-Engeby K, Grunn U, Bauerschlag D, Maass N, Mundhenke C, Jonat W, Bauknecht T: TRAIL-induced apoptosis of ovarian cancer cell lines with selective drug resistance. Geburtshilfe und Frauenheilkunde. 2005, 65 (11): 1064-1073. 10.1055/s-2005-872998.View ArticleGoogle Scholar
- Lee TJ, Jung EM, Lee JT, Kim S, Park JW, Choi KS, Kwon TK: Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther. 2006, 5 (11): 2737-2746. 10.1158/1535-7163.MCT-06-0426.View ArticlePubMedGoogle Scholar
- El-Zawahry A, McKillop J, Voelkel-Johnson C: Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. Bmc Cancer. 2005, 5: 2-10.1186/1471-2407-5-2.View ArticlePubMedPubMed CentralGoogle Scholar
- Voelkel-Johnson C: An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol Ther. 2003, 2 (3): 283-290.View ArticlePubMedGoogle Scholar
- Bai J, Sui J, Demirjian A, Vollmer CM, Marasco W, Callery MP: Predominant Bcl-XL Knockdown Disables Antiapoptotic Mechanisms: Tumor Necrosis Factor‚ÄìRelated Apoptosis-Inducing Ligand‚ÄìBased Triple Chemotherapy Overcomes Chemoresistance in Pancreatic Cancer Cells In vitro. Cancer Research. 2005, 65 (6): 2344-2352. 10.1158/0008-5472.CAN-04-3502.View ArticlePubMedGoogle Scholar
- Xu ZW, Kleeff J, Friess H, Buchler MW, Solioz M: Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Research. 2003, 23 (1A): 251-258.PubMedGoogle Scholar
- Barua S, Rege K: Cancer-cell-phenotype-dependent differential intracellular trafficking of unconjugated quantum dots. Small (Weinheim an der Bergstrasse, Germany). 2009, 5 (3): 370-376.View ArticleGoogle Scholar
- Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, Kirschenbaum S, Silber R, Potmesil M: Dna Topoisomerase Ii-Mediated Interaction of Doxorubicin and Daunorubicin Congeners with Dna. Cancer research. 1989, 49 (21): 5969-5978.PubMedGoogle Scholar
- Kelly MM, Hoel BD, Voelkel-Johnson C: Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther. 2002, 1 (5): 520-527. 10.4161/cbt.1.5.174.View ArticlePubMedGoogle Scholar
- Kim KH, Fisher MJ, Xu SQ, El-Deiry WS: Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clinical Cancer Research. 2000, 6 (2): 335-346.PubMedGoogle Scholar
- Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer research. 1999, 59 (3): 734-741.PubMedGoogle Scholar
- White SJ, Kasman LM, Kelly MM, Lu P, Spruill L, McDermott PJ, Voelkel-Johnson C: Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free Radical Biology and Medicine. 2007, 43 (9): 1313-1321. 10.1016/j.freeradbiomed.2007.06.015.View ArticlePubMedPubMed CentralGoogle Scholar
- Northrop G, Taylor SG, Northrop RL: Biochemical Effects of Mithramycin on Cultured Cells. Cancer research. 1969, 29 (11): 1916-PubMedGoogle Scholar
- Miller DM, Polansky DA, Thomas SD, Ray R, Campbell VW, Sanchez J, Koller CA: Mithramycin selectively inhibits transcription of G-C containing DNA. Am J Med Sci. 1987, 294 (5): 388-394. 10.1097/00000441-198711000-00015.View ArticlePubMedGoogle Scholar
- Fox EJ: Mechanism of action of mitoxantrone. Neurology. 2004, 63 (12): S15-S18.View ArticlePubMedGoogle Scholar
- Valenti M, Cimoli G, Mariani GL, Conte PF, Parodi S, Russo P: Potentiation of Tnf-Mediated Cell-Killing by Mitoxantrone - Relationship to Dna Single-Strand Break Formation. Biochemical pharmacology. 1993, 46 (7): 1199-1206. 10.1016/0006-2952(93)90468-C.View ArticlePubMedGoogle Scholar
- Noviello E, Cimoli G, Cosimi A, Allievi E, Galletti P, Parodi S, Russo P: Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft. Cytokine. 1996, 8 (4): 330-333. 10.1006/cyto.1996.0045.View ArticlePubMedGoogle Scholar
- Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, Hidalgo M, Trent JM, Han HY, Von Hoff DD: Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer Cells. Clinical Cancer Research. 2009, 15 (21): 6519-6528. 10.1158/1078-0432.CCR-09-0077.View ArticlePubMedPubMed CentralGoogle Scholar
- Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J, Tsao MS: Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol. 2000, 157 (5): 1623-1631. 10.1016/S0002-9440(10)64800-6.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/11/470/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.